… have shown promise in overcoming resistance to kinase inhibitors … SHP2 inhibitors are
used to overcome drug resistance, especially to immunotherapy agents. Many SHP2 inhibitors …

… the therapeutic potential of SHP2 inhibitor in overcoming drug resistance of kinase inhibitors
… Also, immune checkpoint inhibitors have been used to treat advanced NSCLC, but about 80…

… mice; tumors intrinsically sensitive to SHP2 inhibition or checkpoint blockade were particularly
… to increase sensitivity to an immune checkpoint inhibitor in checkpoint resistant tumors. …

… resistance occurs to bypass pharmacological inhibition. For … in the tumor microenvironment
and SHP2 inhibition is sufficient to … of SHP2 inhibitors in combination with immune checkpoint …

… SHP2 is critical for either oncogenic signaling or resistance to current targeted agents. SHP2
inhibition … Allosteric SHP2 inhibitors combined with immune checkpoint inhibitors do not …

… and efficacy of SHP2 and KRASG12C inhibition can be … benefit of immune checkpoint
inhibitors (ICI) in PDAC treatment. A … of SHP2, leading to resistance to allosteric SHP2 inhibitors […

… Use of immune checkpoint inhibitors has become more widespread, especially anti–PD-1/…
–SHP-2 would synergize with XRT and anti–PD-L1 therapy to overcome treatment resistance …

… PD-1 is an immune checkpoint protein. … Moreover, the mechanisms underlying
resistance to allosteric SHP2 inhibitors should attract much attention. Although combinatorial …

… B) Diagram showing a genome-wide CRISPR-Cas9 knockout screen and validation to infer
mechanisms of resistance to SHP2 inhibition and to select druggable targets for combination …

… of resistance to PI3K inhibitors, as shown in the preclinical models of metastatic breast cancer
where the combination of PI3K and SHP2 inhibition … therapies such as immune checkpoint …